^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    monepantel (NUZ-001)

    i
    Other names: NUZ-001, PAA1, MPL, NUZ001, NUZ 001
    Associations

    News

    Trials
    Company:
    Neurizon Therapeutics
    Drug class:
    mTOR modulator
    Related drugs:
    Associations

    News

    Trials
    6ms
    Role of the Abcg2 transporter in plasma, milk, and tissue levels of the anthelmintic monepantel in mice. (PubMed, Chem Biol Interact)
    Finally, despite the lack of a difference between groups, we investigated potential differences in MNP and MNPSO2's plasma and tissue accumulation levels between wild-type and Abcg2-/- male mice. In this study, we demonstrated that MNPSO2 milk levels were affected by Abcg2, with potential pharmacological and toxicological consequences, contributing to the undesirable xenobiotic residues in milk.
    Preclinical • Journal
    |
    ABCG2 (ATP Binding Cassette Subfamily G Member 2)
    |
    monepantel (NUZ-001)
    10ms
    An Open Label Extension Study of Monepantel in Individuals With Motor Neurone Disease (clinicaltrials.gov)
    P1, N=12, Recruiting, PharmAust Ltd | Not yet recruiting --> Recruiting
    Enrollment open
    |
    monepantel (NUZ-001)
    1year
    A Study of Monepantel in Individuals With Motor Neurone Disease (clinicaltrials.gov)
    P1, N=12, Completed, PharmAust Ltd | Recruiting --> Completed | Trial completion date: May 2023 --> Nov 2023 | Trial primary completion date: Dec 2022 --> Nov 2023
    Trial completion • Trial completion date • Trial primary completion date
    |
    monepantel (NUZ-001)
    1year
    An Open Label Extension Study of Monepantel in Individuals With Motor Neurone Disease (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, PharmAust Ltd
    New P1 trial
    |
    monepantel (NUZ-001)
    over1year
    Induction of endoplasmic reticulum stress is associated with the anti-tumor activity of monepantel across cancer types. (PubMed, Cancer Med)
    As these outcomes are all associated with mTOR signalling, cell cycle and autophagy, we now provide a likely triggering mechanism for the anti-cancer activity of monepantel.
    Journal
    |
    ATF4 (Activating Transcription Factor 4) • ATG7 (Autophagy Related 7)
    |
    monepantel (NUZ-001)
    over3years
    Monepantel antitumor activity is mediated through inhibition of major cell cycle and tumor growth signaling pathways. (PubMed, Am J Cancer Res)
    MPL treatment led to reduced tumor volume and weights without causing any detectable side effects. Coupled with the recent human safety data published on this molecule, expanded future trials are highly anticipated.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CCND1 (Cyclin D1) • EIF4EBP1 (Eukaryotic translation initiation factor 4E binding protein 1)
    |
    monepantel (NUZ-001)